Skip Navigation



JAC Advance Access published online on March 23, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl111
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/6/1244    most recent
dkl111v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cruciani, M.
Right arrow Articles by Gatti, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cruciani, M.
Right arrow Articles by Gatti, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received November 23, 2005
Revised March 9, 2006
Accepted March 12, 2006

Brief report

Penetration of didanosine in semen of HIV-1-infected men

M. Cruciani 1 *, G. Liuzzi 2, A. Chirianni 3, S. Audagnotto 4, S. Bonora 4, A. Di Biagio 5, A. Sinicco 4, M. Bassetti 5, and G. Gatti 5

1 Centre of Preventive Medicine & HIV Outpatient Clinic, Via Germania, 20-37135 Verona, Italy
2 National Institute for Infectious Diseases, L Spallanzani IRCCS, Rome, Italy
3 III Division of Infectious Diseases, Ospedale Cotugno, Napoli, Italy
4 Department of Infectious Diseases, University of Turin, Turin, Italy
5 Infectious Diseases Department, University of Genoa School of Medicine, San Martino Hospital, Genoa, Italy

* To whom correspondence should be addressed.
M. Cruciani, E-mail: crucianimario{at}virgilio.it


  Abstract

Objectives: The disposition of antiretroviral agents into genital tissue and fluids is one of the factors implicated in the control of viral replication within the male genital tract and should be an objective of highly active antiretroviral therapy. We have investigated didanosine penetration in seminal plasma of 16 HIV-infected patients.

Patients and methods: A total of 16 patients on didanosine (200 mg every 12 h or 400 mg once daily) participated in the pharmacokinetic study. After the didanosine morning dose, peripheral blood plasma and semen plasma were collected within the intervals 0-4, 4-8 and 8-12 h in the twice-daily regimen and 0-4, 4-12 and 12-24 h in the once-daily regimen.

Results: Within each sampling time interval didanosine concentrations in seminal plasma were higher than in blood. The interquartile range of concentrations in seminal plasma was 292-1217 ng/mL, compared with 50-150 ng/mL in blood plasma. Didanosine could be detected in 14 of the 16 semen samples analysed and in 8 of the 16 blood samples.

Conclusions: We have demonstrated that didanosine penetrates into the seminal plasma in higher concentrations than in blood plasma.

Keywords: antiretroviral therapy; pharmacokinetics; drug distribution; sanctuary site.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.